Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
86.44%
-
Total 13F principal
-
$815,214,254
-
Principal change
-
+$14,795,055
-
Total reported market value
-
$706,534,402
-
Number of holders
-
64
-
Value change
-
+$11,603,534
-
Number of buys
-
16
-
Number of sells
-
29
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2023
As of 31 Dec 2023,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
64 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$815,214,254
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, CAMDEN ASSET MANAGEMENT L P /CA, LINDEN ADVISORS LP, Wellesley Asset Management, Invesco Ltd., DAVIDSON KEMPNER CAPITAL MANAGEMENT LP, LAZARD ASSET MANAGEMENT LLC, CITIGROUP INC, AVIVA PLC, and STATE STREET CORP.
This page lists
64
institutional bondholders reporting positions
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.